Dermavant Presents Results of Tapinarof Cream in P-III (PSOARING 3) Trial for the Treatment of Plaque Psoriasis at AAD 2022
Shots:
- The P-III (PSOARING 3) LTE study evaluates tapinarof (1%) vs vehicle-controlled cream in adults patients with PsO for ~40wks. & a 4wks. safety follow-up period. The patients had completed the treatment in the P-III (PSOARING 1 & 2) studies
- The results showed continued improvements for ~52wks. in efficacy outcomes, QoL measures & tolerability scores with no associated tachyphylaxis, were well-tolerated in sensitive skin & intertriginous areas with a majority of patients experiencing no irritation for ~52wks.
- The therapy showed a continued & durable improvement in QoL. The US FDA has accepted an application for tapinarof to treat PsO in Aug 2021 & assigned a PDUFA date in Q2’22
Ref: Globe Newswire | Image: Dermavant
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
